Loading stock data…
QNCX
$1.22-0.11 (-8.27%)
Market ClosedLast close May 4
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quince Therapeutics, Inc. in the Healthcare sector is trading at $1.22. The stock is currently near its 52-week low of $0.80, remaining 92.2% below its 200-day moving average. Technical signals show neutral RSI of 48 and bullish MACD crossover, explaining why QNCX maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.22
Potential Upside
5%
Whystock Fair Value$1.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of ra...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6565.16%
Volume
Today's trading volume
939,430
Recent News
BC-Most Active Stocks
Elong Power Holding Ltd. 329,453,698 0.1034
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital
D. Boral Capital analyst Jason Kolbert raised the firm’s price target on Quince Therapeutics (QNCX) to $5 from $4 and keeps a Buy rating on the shares after the company said the last patient has completed their last visit in the pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate in patients with Ataxia-Telangiectasia. The firm cites the rolling of its valuation metrics out a year for the target bump. Claim 50% Off TipRanks Premium and Invest with Confidenc
June 2025's Promising Penny Stocks For Savvy Investors
As the U.S. markets navigate a landscape marked by geopolitical tensions and fluctuating oil prices, investors are keenly observing shifts in major indices like the Dow Jones and S&P 500. For those interested in exploring beyond established giants, penny stocks—often representing smaller or emerging companies—remain an intriguing investment area despite their somewhat outdated moniker. By focusing on financially robust penny stocks, investors can uncover potential opportunities that balance...